Maryland-based vision research body, ARVO Foundation, has awarded the 2025 Carl Camras Translational Research Award to Indian American researcher, Subrata Batabyal.
The $12,000 award is granted annually to early-career investigators working in areas of translational research.
“I am deeply honored to receive the ARVO 2025 Carl Camras Translational Research Award,” said Batabyal, currently director of nonclinical development at Texas-based Nanoscope Therapeutics. “I remain committed to advancing gene therapies and developing innovative treatment options for patients with inherited retinal diseases.”
He is recognized for his pioneering work on optogenetic vision restoration, a treatment for blindness caused by inherited retinal diseases.
Of his research, Batabyal explains: "Our approach uses an ambient light-sensing protein — Multi-Characteristic Opsin (MCO) — that makes the remaining healthy cells in the damaged retina light-sensitive. The therapy works with regular daylight, requires no special devices, and has shown promising results in clinical trials, offering hope for patients with various forms of inherited blindness."
Also read: American Chemical Society honors Bipin V. Vora with research award
He leads the pre-clinical research and assay development for Nanoscope’s gene therapy platforms. A PhD in Chemistry investigating biomolecular interactions, followed by postdoctoral research in Biophotonics, he focuses on optogenetics, gene delivery, and optical detection of neuronal activation.
Association for Research in Vision and Ophthalmology (ARVO) aims to recognize young researchers who have exhibited excellence in research, and also their fundamental scientific discoveries, concepts and novel technologies which have led to, or have the promise of leading to, clinical application.
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login